Establishing an immune correlate of protection for Nipah virus in nonhuman primates

The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.

Authors

Institutions

Publication Details

Journal
npj Vaccines
Published
2024-12-19
DOI
https://doi.org/10.1038/s41541-024-01036-2
Citations
6
Primary Topic
Virology and Viral Diseases
Type
article
Field-Weighted Citation Impact
2.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Establishing an immune correlate of protection for Nipah virus in nonhuman primates

Christopher C. Broder, Dominique Promeneur, Amara Luckay, B. Small et al.
6 citations
npj Vaccines
Virology and Viral Diseases
2.32
article

Establishing an immune correlate of protection for Nipah virus in nonhuman primates

Christopher C. Broder, Dominique Promeneur, Amara Luckay, B. Small, Victor H. Leyva-Grado, Krystle N. Agans, Robert W. Cross, Michael Egan, Viktoriya Borisevich, Thomas W. Geisbert, Svetlana Hamm, Daniel J. Deer, Antony S. Dimitrov, Glorie G. Lazaro
article en
6 citations

Abstract

The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.

npj VaccinesVol. 9(1)
Henry M. Jackson Foundation (US), Uniformed Services University of the Health Sciences (US), Coalition for Epidemic Preparedness Innovations (NO), Human Immunome Project (US), The University of Texas Medical Branch at Galveston (US)
U.S. Department of Health and Human Services, Henry M. Jackson Foundation, Coalition for Epidemic Preparedness Innovations, National Institutes of Health, Uniformed Services University of the Health Sciences
Good health and well-being
Openalex Percentile: Top 10%
Virology and Viral Diseases
2.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.